Supranodose vagotomy eliminates respiratory depression evoked by dermorphin in anaesthetized rats.

Wojciechowski P, Szereda-Przestaszewska M, Lipkowski AW

European journal of pharmacology17 Feb 2007Cited by 15 (Europe PMC)

PMID17362918DOI10.1016/j.ejphar.2007.02.012PepBankPUB-17362918

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Safety outcome
In anaesthetized rats, intravenous dermorphin evoked apnea.
In plain wordsIn rats, intravenous dermorphin caused apnea.
Peptide
Dermorphin
Outcome
IncreaseApnea
Study
ratn: not reported in source
Spontaneously breathing anaesthetized rats
Outcome group
Adverse events · Respiratory
Studied dose
0.5 mg/kg · intravenous bolusAs given in this study (rat).
Source sentences
Summary
An intravenous dermorphin bolus of 0.5 mg/kg evoked the apnea followed by breathing of reduced rate and compensatory augmentation of tidal volume, which resulted in an invariable minute ventilation.
1 context sentence(design, population, supporting numbers)
Summary · context
The respiratory effects of stimulation of mu-opioid receptors were studied in spontaneously breathing anaesthetized rats that were either neurally intact or subjected to bilateral supranodosal vagotomy.
Report a problemFND-1736291801
02AnimalAnimal study (in vivo)Safety outcome
In anaesthetized rats, intravenous dermorphin reduced breathing rate after apnea.
In plain wordsIn rats, intravenous dermorphin slowed breathing after apnea.
Peptide
Dermorphin
Outcome
DecreaseBreathing rate
Study
ratn: not reported in source
Spontaneously breathing anaesthetized rats
Outcome group
Adverse events · Respiratory
Studied dose
0.5 mg/kg · intravenous bolusAs given in this study (rat).
Source sentences
Summary
An intravenous dermorphin bolus of 0.5 mg/kg evoked the apnea followed by breathing of reduced rate and compensatory augmentation of tidal volume, which resulted in an invariable minute ventilation.
1 context sentence(design, population, supporting numbers)
Summary · context
The respiratory effects of stimulation of mu-opioid receptors were studied in spontaneously breathing anaesthetized rats that were either neurally intact or subjected to bilateral supranodosal vagotomy.
Report a problemFND-1736291802
03AnimalAnimal study (in vivo)Safety outcome
In anaesthetized rats, intravenous dermorphin increased tidal volume as a compensatory response.
In plain wordsIn rats, intravenous dermorphin increased the volume of each breath as a compensatory response.
Peptide
Dermorphin
Outcome
IncreaseTidal volume
Study
ratn: not reported in source
Spontaneously breathing anaesthetized rats
Outcome group
Adverse events · Respiratory
Studied dose
0.5 mg/kg · intravenous bolusAs given in this study (rat).
Source sentences
Summary
An intravenous dermorphin bolus of 0.5 mg/kg evoked the apnea followed by breathing of reduced rate and compensatory augmentation of tidal volume, which resulted in an invariable minute ventilation.
1 context sentence(design, population, supporting numbers)
Summary · context
The respiratory effects of stimulation of mu-opioid receptors were studied in spontaneously breathing anaesthetized rats that were either neurally intact or subjected to bilateral supranodosal vagotomy.
Report a problemFND-1736291803
04AnimalAnimal study (in vivo)Safety outcome
In anaesthetized rats, minute ventilation remained unchanged after intravenous dermorphin.
In plain wordsIn rats, total ventilation per minute remained unchanged after intravenous dermorphin.
Peptide
Dermorphin
Outcome
No significant changeMinute ventilation
Study
ratn: not reported in source
Spontaneously breathing anaesthetized rats
Outcome group
Adverse events · Respiratory
Studied dose
0.5 mg/kg · intravenous bolusAs given in this study (rat).
Source sentences
Summary
An intravenous dermorphin bolus of 0.5 mg/kg evoked the apnea followed by breathing of reduced rate and compensatory augmentation of tidal volume, which resulted in an invariable minute ventilation.
1 context sentence(design, population, supporting numbers)
Summary · context
The respiratory effects of stimulation of mu-opioid receptors were studied in spontaneously breathing anaesthetized rats that were either neurally intact or subjected to bilateral supranodosal vagotomy.
Report a problemFND-1736291804
05AnimalAnimal study (in vivo)Safety outcome
In anaesthetized rats, dermorphin caused hypotension.
In plain wordsIn rats, dermorphin reduced blood pressure.
Peptide
Dermorphin
Outcome
DecreaseBlood pressure
Study
ratn: not reported in source
Spontaneously breathing anaesthetized rats
Outcome group
Blood pressure · Cardiovascular
Studied dose
0.5 mg/kg · intravenous bolusAs given in this study (rat).
Source sentences
Summary
Cardiovascular effects consisted of hypotension and temporary fall in heart rate.
1 context sentence(design, population, supporting numbers)
Summary · context
The respiratory effects of stimulation of mu-opioid receptors were studied in spontaneously breathing anaesthetized rats that were either neurally intact or subjected to bilateral supranodosal vagotomy.
Report a problemFND-1736291805
06AnimalAnimal study (in vivo)Safety outcome
In anaesthetized rats, dermorphin caused a temporary fall in heart rate.
In plain wordsIn rats, dermorphin temporarily reduced heart rate.
Peptide
Dermorphin
Outcome
DecreaseHeart rate
Study
ratn: not reported in source
Spontaneously breathing anaesthetized rats
Outcome group
Heart function · Cardiovascular
Studied dose
0.5 mg/kg · intravenous bolusAs given in this study (rat).
Source sentences
Summary
Cardiovascular effects consisted of hypotension and temporary fall in heart rate.
1 context sentence(design, population, supporting numbers)
Summary · context
The respiratory effects of stimulation of mu-opioid receptors were studied in spontaneously breathing anaesthetized rats that were either neurally intact or subjected to bilateral supranodosal vagotomy.
Report a problemFND-1736291806
07AnimalAnimal study (in vivo)Safety outcome
In rats after supranodosal vagotomy, dermorphin did not evoke respiratory effects.
In plain wordsIn rats after supranodosal vagotomy, dermorphin did not affect breathing.
Peptide
Dermorphin
Outcome
No significant changeRespiratory effects after supranodosal vagotomy
Study
ratn: not reported in source
Rats after bilateral supranodosal vagotomy
Outcome group
Adverse events · Respiratory
Studied dose
0.5 mg/kg · intravenous bolusAs given in this study (rat).
Source sentences
Summary
In rats initially treated by supranodosal vagotomy, dermorphin did not evoke any respiratory and cardiovascular effects.
1 context sentence(design, population, supporting numbers)
Summary · context
The respiratory effects of stimulation of mu-opioid receptors were studied in spontaneously breathing anaesthetized rats that were either neurally intact or subjected to bilateral supranodosal vagotomy.
Report a problemFND-1736291807
08AnimalAnimal study (in vivo)Safety outcome
In rats after supranodosal vagotomy, dermorphin did not evoke cardiovascular effects.
In plain wordsIn rats after supranodosal vagotomy, dermorphin did not cause cardiovascular effects.
Peptide
Dermorphin
Outcome
No significant changeCardiovascular effects after supranodosal vagotomy
Study
ratn: not reported in source
Rats after bilateral supranodosal vagotomy
Outcome group
Adverse events · Cardiovascular
Studied dose
0.5 mg/kg · intravenous bolusAs given in this study (rat).
Source sentences
Summary
In rats initially treated by supranodosal vagotomy, dermorphin did not evoke any respiratory and cardiovascular effects.
1 context sentence(design, population, supporting numbers)
Summary · context
The respiratory effects of stimulation of mu-opioid receptors were studied in spontaneously breathing anaesthetized rats that were either neurally intact or subjected to bilateral supranodosal vagotomy.
Report a problemFND-1736291808

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
27 Oct 2026, 18:20 UTC
Study results updated
Version 1
27 Oct 2026, 16:32 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.